Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
Cepheid (NASDAQ: CPHD) today announced that the U.S. Food & Drug Administration (FDA) has cleared its GeneXpert® Infinity-80 System, a high-throughput automated molecular system designed to deliver around-the-clock results for a wide variety of clinical testing applications. The GeneXpert Infinity-80 has been initially cleared in conjunction with Cepheid's Xpert® Flu test.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.